

Author Index Volume 15 (2013)

Akhtar, Z., CJD virus, contaminated medicine and prevention technology	(1,2)	37– 50
Casteels, B. and S. Rohde, The medical devices regulation in the EU – the evolution of the Regulatory framework for medical devices	(1,2)	85– 92
Daemmrich, A., see M. Oehlrich	(3,4)	93– 95
Daemmrich, A., U.S. healthcare reform and the pharmaceutical market: Projections from institutional history	(3,4)	137–162
Faeh, A., A single European pharmaceutical market: Does maximum harmonization enhance medicinal product innovation?	(1,2)	7– 27
Ghazarian, L. and C. Koenig, EU marketing authorization subsequent to dissolution of the transferor and prior to effective transfer	(1,2)	29– 35
Heible, C., Pharmacologic-technical progress and the economics of growth	(3,4)	103–125
Koenig, C., see Ghazarian, L.	(1,2)	29– 35
López, M.D.C., Pharmacovigilance and risk management in the EU	(1,2)	71– 84
Matsuyama, A., Translational research in regenerative medicine: A translational gap	(3,4)	163–172
Oehlrich and A. Daemmrich, Legal and political competitiveness for pharmaceuticals	(3,4)	93– 95
Oehlrich, M., Induced innovation of the German Employees' Invention Act	(3,4)	127–135
Oehlrich, M., Introduction	(3,4)	99–102
Rohde, S., see Casteels, B.	(1,2)	85– 92

- Sprecher, F., Orphan drugs and paediatric medicinal products (3,4) 173–194
- Valverde, J.L., The pharmaceuticals industry in trouble (1,2) 51– 69